Indaptus Therapeutics (NASDAQ:INDP) Rating Increased to Hold at Wall Street Zen

Indaptus Therapeutics (NASDAQ:INDP) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Trading Up 3.8%

INDP opened at $2.32 on Friday. The business has a 50 day moving average of $3.07 and a 200-day moving average of $6.75. The stock has a market capitalization of $4.05 million, a price-to-earnings ratio of -0.06 and a beta of 1.00. Indaptus Therapeutics has a 1-year low of $1.65 and a 1-year high of $47.60.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Wednesday, November 12th. The company reported ($2.98) EPS for the quarter, beating the consensus estimate of ($4.17) by $1.19. Equities analysts predict that Indaptus Therapeutics will post -1.79 EPS for the current year.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.